

RECEIVED

SEP 03 1999

1617

PATENT

TECH CENTER 1600/2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Achari et al.

Examiner: Unassigned

Serial No.: 09/334,537

Group Art Unit: Unassigned

Filed: June 16, 1999

Docket No.: 719-163

For: PHARMACEUTICAL FORMULATIONS  
AND METHODS COMPRISING  
INTRANASAL MORPHINE

Dated: August 27, 1999

#2  
AKO  
9-8-99

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

**UNITED STATES PATENTS**

<b><u>PATENTEE</u></b>	<b><u>PATENT NO.</u></b>	<b><u>ISSUE DATE</u></b>
Hussain	4,464,378	August 7, 1984
Morella et al.	5,202,128	April 13, 1993
Illum	5,629,011	May 13, 1997
Hill	5,880,132	March 9, 1999

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:  
Assistant Commissioner for Patents, Washington, D.C.

20231 on

August 27, 1999

Dated:

8/27/99, G.M. Toria


**NON-PATENT REFERENCES**

Banker & Rhodes, Modern Pharmaceutics, Ch. 2, p. 40 (1979).

The above-listed references are also listed on Applicants' Substitute Form PTO-1449, which is attached to this Information Disclosure Statement.

As a result of this submission, Applicants respectfully submit that the application is in all respects in condition for examination on the merits.

Respectfully submitted,



Samir R. Patel

Reg. No. P-44,998

Attorney for Applicant

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, NY 11791

(516) 822-3550